Developing a novel therapy against solid tumors

You are here

Over 90% of all human cancers are solid tumors. Given the heterogenicity and prevalence of the disease, the development of new anticancer approaches to tackle this condition is highly needed.  

A new mechanism of oncogenic activation was discovered by the group led by Pere Roca-Cusachs from  the Institute of Bioengineering of Catalonia (IBEC). In the mentioned pathway, mechanical cues trigger interaction between proteins vinculin and talin, with the resulting activation of the oncogene YAP. Given the presence of this oncogenic activation in most solid tumors, the interaction between talin and vinculin has been proposed as a promising target to slow down, stop or even reverse tumor growth.

For this purpose, Iproteos has enrolled in a public-private consortium altogether with the IBEC and the Vall d’Hebron Research Institute (VHIR). Iproteos’ proprietary platform IPROTech will address the design, synthesis and characterization of suitable candidate drugs for this new cancer therapy strategy.


Mechanical regulation of a molecular clutch defines force transmission and transduction in response to matrix rigidity. (Nature Cell Biology, April 2016).